Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2015
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Horizant
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2015
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Details : Undisclosed
Product Name : Horizant
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2015
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XP23829
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2014
Lead Product(s) : XP23829
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2012
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gabapentin
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2012
Lead Product(s) : Gabapentin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2011
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2011
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2011
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2011
Lead Product(s) : Gabapentin Enacarbil
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
